Can You Get Shingles Without a Rash If You're Vaccinated?
Yes, it is theoretically possible to develop shingles without a rash (zoster sine herpete) even after vaccination, though this is extremely rare and the Shingrix vaccine provides 92% effectiveness against all forms of herpes zoster, meaning breakthrough cases of any type occur in only about 8% of vaccinated individuals. 1
Understanding Breakthrough Shingles After Vaccination
The recombinant zoster vaccine (Shingrix) demonstrates 92% effectiveness at preventing herpes zoster at 3.2 years of follow-up, which means approximately 8 out of 100 vaccinated people might still develop some form of shingles compared to the unvaccinated population. 1 This residual risk exists because:
- Vaccine-induced immunity varies between individuals based on baseline immune function, age, and concurrent immunosuppressive conditions, with cell-mediated immune responses correlating most strongly with protection. 1
- Even highly effective vaccines cannot provide 100% protection against viral reactivation in all individuals. 1
Zoster Sine Herpete (Shingles Without Rash)
While the provided evidence does not specifically address rash-free shingles in vaccinated individuals, we know from general medical knowledge that zoster sine herpete is a recognized clinical entity where patients experience:
- Dermatomal pain, numbness, or tingling without visible skin lesions
- Neurological symptoms consistent with varicella-zoster virus reactivation
- Diagnosis typically confirmed through elevated VZV antibody titers or PCR testing
The key clinical point is that vaccinated individuals who develop breakthrough shingles generally experience less severe disease and lower rates of post-herpetic neuralgia compared to unvaccinated individuals. 1
Clinical Implications for Vaccinated Patients
- Patients on disease-modifying antirheumatic drugs (DMARDs) or other immunosuppressive medications may have reduced vaccine responses and remain at higher baseline risk for herpes zoster even after vaccination, though vaccination still provides meaningful protection. 1
- Immunocompromised individuals should still receive the full 2-dose Shingrix series because it provides substantial risk reduction despite not being 100% effective. 1
Important Caveats
- The live attenuated vaccine (Zostavax) shows only 51% effectiveness and drops to 14.1% efficacy by year 10, making breakthrough cases much more common with this older vaccine. 1
- Adults who received Zostavax should still receive the full 2-dose Shingrix series because the older vaccine provides inadequate long-term protection, with Shingrix administered at least 2 months after Zostavax. 1
- Having shingles once (with or without rash) does not provide reliable protection against future episodes, with a 10-year cumulative recurrence risk of 10.3%, and vaccination is recommended after a shingles episode once acute symptoms resolve. 1
Bottom Line for Clinical Practice
While zoster sine herpete can theoretically occur in vaccinated individuals as part of the 8% breakthrough rate, the Shingrix vaccine provides excellent protection against all manifestations of herpes zoster. 1 Any vaccinated patient presenting with dermatomal pain or neurological symptoms should still be evaluated for possible herpes zoster reactivation, but the likelihood is substantially reduced compared to unvaccinated individuals.